Penaud-Budloo, Magalie
Broucque, Frédéric
Harrouet, Katell
Bouzelha, Mohammed
Saleun, Sylvie
Douthe, Sandy
D’Costa, Susan
Ogram, Sushma
Adjali, Oumeya
Blouin, Véronique
Lock, Martin
Snyder, Richard O.
Ayuso, Eduard
Article History
Received: 18 December 2018
Revised: 5 March 2019
Accepted: 8 March 2019
First Online: 29 March 2019
Compliance with ethical standards
:
: ROS is an inventor on patents related to recombinant AAV technology. ROS owns equity in a gene therapy company that is commercializing AAV for gene therapy applications. To the extent that the work in this manuscript increases the value of these commercial holdings, ROS has a conflict of interest. ML is an inventor on patents related to recombinant AAV technology. The other authors declare that they have no conflict of interest.